Document Detail

Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis.
MedLine Citation:
PMID:  23363664     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Autologous haemopoietic stem-cell transplantation (HSCT) benefits patients with systemic sclerosis but has been associated with significant treatment-related mortality and failure to improve diffusion capacity of carbon monoxide (DLCO). We aimed to assess efficacy of HSCT and use of rigorous cardiac screening in this group.
METHODS: We assessed patients with diffuse systemic sclerosis or limited systemic sclerosis and interstitial lung disease who were treated with HSCT as part of a study or on a compassionate basis at Northwestern University (Chicago, IL, USA) or the University of São Paulo (Ribeirão Preto, Brazil). Unselected peripheral blood stem cells were harvested with cyclophosphamide (2 g/m(2)) and filgrastim. The transplant regimen was a non-myeloablative regimen of cyclophosphamide (200 mg/kg) and rabbit anti-thymocyte globulin (rATG; 4·5-6·5 mg/kg). We followed patients up to 5 years for overall survival, relapse-free survival, modified Rodnan skin score, and pulmonary function tests.
FINDINGS: Five (6%) of 90 patients died from treatment-related causes. Despite standard guidelines that recommend echocardiogram for screening before transplantation, four treatment-related deaths occurred because of cardiovascular complications (one constrictive pericarditis, two right heart failures without underlying infection, and one heart failure during mobilisation), and one death was secondary to sepsis without documented underlying heart disease. Kaplan-Meier analysis showed survival was 78% at 5 years (after eight relapse-related deaths) and relapse-free survival was 70% at 5 years. Compared with baseline, we noted improvements after HSCT in modified Rodnan skin scores at 1 year (58 patients; p<0·0001), 2 years (42 patients; p<0·0001), and 3 years (27 patients; p<0·0001) and forced vital capacity at 1 year (58 patients; p=0·009), 2 years (40 patients; p=0·02), and 3 years (28 patients; p=0·004), but total lung capacity and DLCO were not improved significantly after HSCT. Overall mean DLCO was significantly improved in patients with normal baseline echocardiograms (p=0·005) or electrocardiographs (p=0·05).
INTERPRETATION: Autologous HSCT with a non-myeloablative regimen of cyclophosphamide and rATG with a non-selected autograft results in sustained improvement in skin thickness and forced vital capacity. DLCO is affected by baseline cardiac function. Guidelines for cardiac screening of patients with systemic sclerosis to assess treatment-related risk from pulmonary artery hypertension, primary cardiac involvement, or pericardial disease should be reconsidered and updated.
Richard K Burt; Maria Carolina Oliveira; Sanjiv J Shah; Daniela A Moraes; Belinda Simoes; Mihai Gheorghiade; James Schroeder; Eric Ruderman; Dominique Farge; Z Jessie Chai; Zora Marjanovic; Sandeep Jain; Amy Morgan; Francesca Milanetti; Xiaoqiang Han; Borko Jovanovic; Irene B Helenowski; Julio Voltarelli
Related Documents :
12618974 - The transcervical incision for use in oral and maxillofacial surgical procedures.
10982934 - Early treatment of vertical skeletal dysplasia: the hyperdivergent phenotype.
20430504 - Comparison of a single noncompression miniplate versus 2 noncompression miniplates in t...
20131954 - Postural stability in patients with ankylosing spondylitis.
16390674 - A single nutrition counseling session with a registered dietitian improves short-term c...
18000724 - Intragastric balloon insertion increases the frequency of erosive esophagitis in obese ...
Publication Detail:
Type:  Comparative Study; Journal Article     Date:  2013-01-28
Journal Detail:
Title:  Lancet     Volume:  381     ISSN:  1474-547X     ISO Abbreviation:  Lancet     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-04-01     Completed Date:  2013-04-08     Revised Date:  2013-07-01    
Medline Journal Info:
Nlm Unique ID:  2985213R     Medline TA:  Lancet     Country:  England    
Other Details:
Languages:  eng     Pagination:  1116-24     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2013 Elsevier Ltd. All rights reserved.
Division of Immunotherapy, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cause of Death*
Compassionate Use Trials
Follow-Up Studies
Heart Failure / mortality*
Hematopoietic Stem Cell Transplantation / methods*,  mortality*
Kaplan-Meier Estimate
Middle Aged
Pericarditis, Constrictive / mortality*
Peripheral Blood Stem Cell Transplantation / methods*,  mortality*
Pulmonary Diffusing Capacity / physiology
Retrospective Studies
Scleroderma, Diffuse / mortality*,  physiopathology,  therapy*
Scleroderma, Limited / mortality*,  physiopathology,  therapy*
Sepsis / mortality*
Total Lung Capacity
Transplantation Conditioning*
Transplantation, Autologous
Vital Capacity / physiology
Young Adult
Comment In:
Lancet. 2013 Jun 15;381(9883):2080   [PMID:  23769229 ]
Lancet. 2013 Jun 15;381(9883):2080-1   [PMID:  23769228 ]
Lancet. 2013 Jun 15;381(9883):2079-80   [PMID:  23769227 ]
Dtsch Med Wochenschr. 2013 May;138(21):1094   [PMID:  23677501 ]
Lancet. 2013 Mar 30;381(9872):1081-3   [PMID:  23363663 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Gender Differences in the Clinical Characteristics and Outcomes of Patients With Vasospastic Angina.
Next Document:  Daily chlorhexidine bathing to reduce bacteraemia in critically ill children: a multicentre, cluster...